These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12669362)

  • 1. [Pneumococcal vaccination in France among adults].
    Dubois G
    Bull Acad Natl Med; 2002; 186(8):1461-76; discussion 1476-7. PubMed ID: 12669362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
    Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing pneumococcal disease. ACIP recommends pneumococcal polysaccharide vaccine for all adults age > or = 65.
    Whitney CG
    Geriatrics; 2003 Oct; 58(10):20-2, 25. PubMed ID: 14569639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people.
    Ridda I; Lindley IR; Gao Z; McIntyre P; Macintyre CR
    Vaccine; 2008 Oct; 26(44):5633-40. PubMed ID: 18706955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antipneumococcal vaccine: up date and prospective].
    Caramia G; Pastorelli G
    Minerva Pediatr; 2005 Oct; 57(5):229-41. PubMed ID: 16205607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Education does pay off: pneumococcal vaccine screening and administration in hospitalized adult patients with pneumonia.
    Kruspe R; Lillis R; Daberkow DW; Blais CM; Wilbright W; Gupta S; Gould CA; Sun T; Martinez JA; deBoisblanc B; Ladabaum U; Sanders CV; Lopez FA
    J La State Med Soc; 2003; 155(6):325-31. PubMed ID: 14750752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adults with invasive pneumococcal disease: missed opportunities for vaccination.
    Kyaw MH; Greene CM; Schaffner W; Ray SM; Shapiro M; Barrett NL; Gershman K; Craig AS; Roberson A; Zell ER; Schuchat A; Bennett NM; Whitney CG;
    Am J Prev Med; 2006 Oct; 31(4):286-92. PubMed ID: 16979452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pneumococcal disease and asplenia: the importance of vaccination.
    Clarke SC; Christie P; Edwards GF
    Health Bull (Edinb); 2001 Jan; 59(1):49-52. PubMed ID: 12811911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with diabetes or asthma--United States, 2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2004 Nov; 53(43):1007-12. PubMed ID: 15525897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal vaccination: effective in children under the age of 2 years.
    Prescrire Int; 2009 Dec; 18(104):266. PubMed ID: 20027709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia.
    Andrews RM; Counahan ML; Hogg GG; McIntyre PB
    Vaccine; 2004 Nov; 23(2):132-8. PubMed ID: 15531029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting.
    Mangtani P; Roberts JA; Hall AJ; Cutts FT
    Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza and pneumococcal vaccine coverages in geriatric health care settings in france.
    Gavazzi G; Wazieres B; Lejeune B; Rothan-Tondeur M
    Gerontology; 2007; 53(6):382-7. PubMed ID: 17622768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.
    Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF
    Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
    Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
    Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe.
    Rose M; Zielen S
    Expert Rev Vaccines; 2009 Oct; 8(10):1351-64. PubMed ID: 19803758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.